Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

1.300 -0.050 (-3.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 216,202
Open 1.330
Bid (Size) 1.300 (2)
Ask (Size) 1.330 (3)
Prev. Close 1.350
Today's Range 1.300 - 1.350
52wk Range 0.5950 - 4.180
Shares Outstanding 27,567,728
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the BIO International Convention
From Werewolf Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-16.7%
-16.7%
1 Month
+19.3%
+19.3%
3 Month
+54.8%
+54.8%
6 Month
-3.0%
-3.0%
1 Year
-51.5%
-51.5%

More News

Read More
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Where Werewolf Therapeutics Stands With Analysts
Via Benzinga
Top movers in Tuesday's after hours session
Via Chartmill
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Werewolf Therapeutics, Inc. - Common Stock publicly traded?
Yes, Werewolf Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Werewolf Therapeutics, Inc. - Common Stock trade on?
Werewolf Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Werewolf Therapeutics, Inc. - Common Stock?
The ticker symbol for Werewolf Therapeutics, Inc. - Common Stock is HOWL on the Nasdaq Stock Market
What is the current price of Werewolf Therapeutics, Inc. - Common Stock?
The current price of Werewolf Therapeutics, Inc. - Common Stock is 1.300
When was Werewolf Therapeutics, Inc. - Common Stock last traded?
The last trade of Werewolf Therapeutics, Inc. - Common Stock was at 07/29/25 04:00 PM ET
What is the market capitalization of Werewolf Therapeutics, Inc. - Common Stock?
The market capitalization of Werewolf Therapeutics, Inc. - Common Stock is 35.84M
How many shares of Werewolf Therapeutics, Inc. - Common Stock are outstanding?
Werewolf Therapeutics, Inc. - Common Stock has 36M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.